Please try another search
Gene Biotherapeutics Inc. is a clinical-stage biotechnology company, which is focused on pre-clinical, clinical and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The technology platform is designed to biologically activate the human body's innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for advanced tissue engineering applications. Its lead product candidate Generx (Ad5FGF-4) is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. The Generx product candidate is under clinical development, which is cleared by the United States Food and Drug Administration (FDA) for a Phase III clinical study.
Name | Age | Since | Title |
---|---|---|---|
Gabor M. Rubanyi | 74 | 2006 | Chairman of Scientific Advisory Board |
Claudio Basilico | - | 2006 | Member of Scientific Advisory Board |
William Sessa | - | 2006 | Member of Scientific Advisory Board |
Richard A. Schatz | - | 2008 | Member of the Scientific Advisory Board |
Wolfgang Schaper | - | 2006 | Member of Scientific Advisory Board |
Kaushik K. Vyas | 65 | 2020 | Independent Director |
Seppo Yla-Herttuala | 65 | 2006 | Member of Scientific Advisory Board |
H. Daniel Perez | 71 | 2006 | Member of Scientific Advisory Board |
James L. Grainer | 66 | 2020 | Chairman, CFO & Secretary |
Christopher J. Reinhard | 68 | 2003 | Co-Founder, CEO, President, Treasurer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review